Epidermal growth factor receptor (EGFR) mutations (EGFRm+) occur in 10–35% of non-
small-cell lung cancer (NSCLC) cases and confer sensitivity to EGFR tyrosine kinase …

Although targeted therapy is standard of care in a large subset of oncogenic addicted non-
small cell lung cancers (NSCLC), until recently, this therapeutic approach has not been …

Opinion statement Non-small cell lung cancer (NSCLC) harboring epidermal growth
receptor (EGFR) mutation has distinct genomic characteristics. Introduction of systemic …

Emergence of acquired resistance is virtually inevitable in patients with a mutation in the
epidermal growth factor receptor gene (EGFR) treated with EGFR tyrosine kinase inhibitors …

Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …

Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined
predictive and druggable mutations that greatly modified patient prognoses. The most …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Background EGFR mutations cause inconsistent response to EGFR tyrosine-kinase
inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR …

Discovery of sensitizing mutations in epidermal growth factor receptor (EGFR) and the
subsequent development of EGFR tyrosine kinase inhibitors (TKIs) have substantially …

Background The strong association between smoking history and the presence of epidermal
growth factor receptor (EGFR) mutations has been proven in non–small-cell lung cancer …